Product description The present Competitive Intelligence Report about Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig’s disease provides a competitor evaluation about new treatments in the R&D pipeline of amyotrophic lateral sclerosis (ALS) / Lou Gehrig’s disease as of March 2009. Amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease) is a rapidly progressing, motor neuron disease characterized by the gradual degeneration and death of motor neurons. When muscles in the diaphragm and chest wall fail, patients lose the ability to breathe without ventilatory support. Most people with ALS die from respiratory failure. Approximately 120, 000 new cases are diagnosed each year. No cure has yet been found for ALS. There is one FDA approved drug, riluzole, that modestly slows the progression of ALS. Quite a number of approaches to treat ALS are being investigated in clinical trials: of the 20 different approaches, the majority (16) are small molecule based treatments, followed by biologics such as proteins, peptides and antibodies and more recently cell-based therapies have emerged for clinical testing. Among the targets being clinically tested are glutamate based therapies, antioxidants, cellular energy regulators, immunomodulators and neuroprotective/neurotrophic therapies. Biologic therapies study the neuroprotective effects of VEGF or are directed at the misfolded superoxide dismutase (SOD-1) among other approaches. Cellular therapies intent to induce regeneration of neuronal cells and tissues. The report includes a compilation of current active projects in research and development of small molecules, antibodies, proteins, peptides, vaccines and other biologics including cells for treatment of amyotrophic lateral sclerosis (ALS). In addition, the report lists company-specific R&D pipelines of new treatments of ALS. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information. Index Small Molecule Approaches for Treatment of ALS Biologics for Treatment of ALS Cellular Approaches for ALS Therapy Corporate R&D Pipelines of New Treatments for ALS About La Merie

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Competitor Analysis: Amyotrophic Lateral Sclerosis (ALS) / Lou
Gehrig`s disease
Published on March 2009
Report Summary
Product description
The present Competitive Intelligence Report about Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig’s disease provides a
competitor evaluation about new treatments in the R&D pipeline of amyotrophic lateral sclerosis (ALS) / Lou Gehrig’s disease
as of March 2009.
Amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease) is a rapidly progressing, motor neuron disease characterized by
the gradual degeneration and death of motor neurons. When muscles in the diaphragm and chest wall fail, patients lose the ability to
breathe without ventilatory support. Most people with ALS die from respiratory failure. Approximately 120, 000 new cases are
diagnosed each year. No cure has yet been found for ALS. There is one FDA approved drug, riluzole, that modestly slows the
progression of ALS.
Quite a number of approaches to treat ALS are being investigated in clinical trials: of the 20 different approaches, the majority (16)
are small molecule based treatments, followed by biologics such as proteins, peptides and antibodies and more recently cell-based
therapies have emerged for clinical testing. Among the targets being clinically tested are glutamate based therapies, antioxidants,
cellular energy regulators, immunomodulators and neuroprotective/neurotrophic therapies. Biologic therapies study the
neuroprotective effects of VEGF or are directed at the misfolded superoxide dismutase (SOD-1) among other approaches. Cellular
therapies intent to induce regeneration of neuronal cells and tissues.
The report includes a compilation of current active projects in research and development of small molecules, antibodies, proteins,
peptides, vaccines and other biologics including cells for treatment of amyotrophic lateral sclerosis (ALS). In addition, the report lists
company-specific R&D pipelines of new treatments of ALS. Competitor projects are listed in a tabular format providing information on:
Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product Category, Indication, R&D Stage
and additional comments with a hyperlink leading to the source of information.
Index Small Molecule Approaches for Treatment of ALS Biologics for Treatment of ALS Cellular Approaches for ALS
Therapy Corporate R&D Pipelines of New Treatments for ALS About La Merie
Competitor Analysis: Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig`s disease Page 1/3

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Competitor Analysis: Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig`s disease
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 250.00 Quantity: _____
Site License--USD 500.00 Quantity: _____
Corporate License--USD 750.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Competitor Analysis: Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig`s disease Page 2/3

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Competitor Analysis: Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig`s disease Page 3/3